Combination therapy of immune checkpoint inhibitors: from rationale to practice

ZHU Xiaodong; CHEN Siyuan

doi:10.19401/j.cnki.1007-3639.2020.12.001

您当前的位置：

首页 >

文章列表页 >

Combination therapy of immune checkpoint inhibitors: from rationale to practice

更新时间：2026-01-27

- Combination therapy of immune checkpoint inhibitors: from rationale to practice
- China Oncology Vol. 30, Issue 12, Pages: 969-976(2020)
- 作者机构：
  
  复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2020.12.001
  CLC：
- Published Online：07 January 2021，
  
  Published：07 January 2021
- 稿件说明：
移动端阅览
朱晓东, 陈思元. 免疫检查点抑制剂联合治疗：从机制到临床[J]. 中国癌症杂志, 2020, 30(12): 969-976.

ZHU Xiaodong, CHEN Siyuan. Combination therapy of immune checkpoint inhibitors: from rationale to practice[J]. China Oncology, 2020, 30(12): 969-976.
朱晓东, 陈思元. 免疫检查点抑制剂联合治疗：从机制到临床[J]. 中国癌症杂志, 2020, 30(12): 969-976. DOI： 10.19401/j.cnki.1007-3639.2020.12.001.

ZHU Xiaodong, CHEN Siyuan. Combination therapy of immune checkpoint inhibitors: from rationale to practice[J]. China Oncology, 2020, 30(12): 969-976. DOI： 10.19401/j.cnki.1007-3639.2020.12.001.

摘要

Abstract

Key words: Immunotherapy

Programmed death-1

Cytotoxic T-lymphocyte-associated protein 4

Melanoma

Gastrointestinal neoplasms

Lung neoplasms

关键词

Keywords

references

Views

3591

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer

The correlation of NF-κB/p65, PD-1 and PD-L1 expressions and their clinical significance in diffuse large B-cell lymphoma

Related Author

义维丽

赵文成

黄东宁

覃　莉

吴新天

周　斐

吴凤英

王　平

Related Institution

柳州市工人医院肿瘤科

同济大学附属上海市肺科医院肿瘤科

贵州医科大学病理学教研室

AI问答

⁰